I'm a personal trainer who gained over 50 pounds while pregnant. Being kind to myself made getting fit again much easier.
She embraced feeling like a beginner again and saw herself as her only competition.
Ricketts prioritized rebuilding her strength in a new body rather than trying to "bounce back."
This as-told-to essay is based on a conversation with Emily Ricketts, a 32-year-old personal trainer and mom of two based in the UK. The following has been edited for length and clarity.
I haven't always been fit and active. Growing up, I hated sports and used to fake sick notes to get out of them at school. I was always just a little bit chubbier than other kids and always the biggest of my friends.
In my early 20s, I got into a bad cycle of trying fad diets and supposed quick fixes like juice cleanses. I abused my body with excessive cardio, and I ended up yo-yoing from one extreme to the other.
But when, in my mid-20s, I met my future husband something clicked. He was really into strength training. I saw him lift weights and feel strong, and I thought, "Why can't I do that?" So I did. And I learned more about fueling my body with enough food, especially protein.
As a newbie, I made great progress, even just from working out at home with dumbbells. My body started to change really quickly.
I started posting about what I was doing on Instagram because I felt so encouraged by the changes I was making and how empowered I felt, and my following grew and grew.
At the time, I had an office job and everyone made fun of me. I'd hide in the toilet to post content. But I kept going: I qualified as a personal trainer, and in 2019, I quit my job to focus full-time on social media and fitness.
Six years on, I've learned that your training and fitness have to evolve based on the season of your life. As a mom of two young girls, I feel passionately about exercise as a means of empowerment, not punishment.
In the fall of 2021, I got pregnant, and I was completely naive going into it. I had no idea that something so amazing could make you feel so utterly awful. I was cripplingly sick, vomiting for nine months, and looking back, I don't know how I did it. It was really scary. Doctors kept telling me the sickness would go, but it didn't.
I kept as active as I could, doing gentle walks and shorter, lighter, less intense strength workouts. I only did what would energize me, because pregnancy is already so exhausting.
I did my pregnancy and postpartum training qualifications, which were eye-opening and helped me understand how much was going on in my body. For example, even in the first trimester when from the outside your body might look the same as before pregnancy, so much is happening inside.
Fortunately, giving birth to Ruby in June 2022 went smoothly, but afterward, I felt like I was back at square one fitness-wise. I actually really enjoyed that, though. There are very few times in your life when you get to experience being a beginner again at something you've already learned.
It was really humbling to go into those first workouts and find, say, a bodyweight squat hard, or pick up some dumbbells and find my old warm-up weight really heavy.
But I kept telling myself that it wasn't about what I could do before, it was about what I could do right now. I had to show up and meet my body where it was.
"It's my journey, my pace, I just have to keep showing up," I told myself.
I'd gained over 50 pounds while pregnant, and my body definitely did not "bounce back" afterward, as women are often pressured to do. It was a really slow, steady process.
As a society, we celebrate pregnant women. We tell them they're beautiful and blooming and rub their bumps. But as soon as that baby is earthside, that same woman and that same body are judged for actually looking like she's had a baby, which is so normal.
I still had a six-month pregnant belly when I was six weeks postpartum, and it does make you feel vulnerable.
I breastfed Ruby for 10 months, which meant I needed to be with her pretty much all the time. It also meant I had to navigate suddenly having big boobs and having to avoid certain exercises which weren't comfortable any more. I had to get to know a new, constantly changing body.
I wanted to be in a slight calorie deficit to gradually lose some of the body fat I'd gained, but it was hard to know what that looked like while breastfeeding. So I just listened to my body, played the long game, and made nourishing Ruby the priority. I made simple meals that I could eat with one hand, like bagels and smoothies.
About a year later, I'd lost the weight I gained.
At the end of 2023, I got pregnant again, and this time I felt a lot more prepared. The sickness was more intense, but at least this time I knew it would go away after my baby was born. I followed my own pregnancy workout guide and had confidence in my body because I'd done it before.
Toward the end of my second pregnancy, I started doing circuit-style training, so 30 seconds on and 30 seconds off. The idea was to prepare myself psychologically for the stop-start nature of contractions. I would choose as many rounds as I felt I could do each day.
Rosie was born in August 2024. I gained over 40 pounds while pregnant, and I was back at square one again, only this time with two little ones demanding my time and attention, which made things harder. I never train for more than 30 minutes because I don't have more time than that.
Nearly a year on, my body definitely looks like someone who's had two babies. I've got more loose skin and stretch marks. But I tell myself what I tell other people: My tummy has had the privilege of growing my babies and feeling them kick, and they're healthy and thriving. As much as I might find my boobs uncomfortable, they're nourishing my baby.
I want to make motherhood my strongest era yet. Becoming a mom has given me a different perspective. I'm not training to change how my body looks; it's for how my daughters look at me while I'm doing it. Ruby already tries to copy me doing push-ups and planks.
I want them to grow up knowing that exercise is a pleasure, not punishment. It's not something they need to abuse their bodies with. And I don't want them to go into workouts like I did, thinking, "I'm only doing this because I hate my thighs." I want them to go into a workout thinking, "I'm doing this because I love how strong squats make me feel."
That, for me, is the best kind of motivation.
Read the original article on Business Insider
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Kate Middleton Reveals She Can No Longer 'Function Normally' After 'Really Difficult' Cancer Battle
Kate Middleton recently opened up about the challenges following her cancer treatment, admitting that recovery has been far from easy. Though now cancer-free, she's still adjusting and carefully managing her return to public life, as seen in her surprise withdrawal from Royal Ascot. Meanwhile, Kate Middleton and Prince William are quietly preparing for their future roles as king and queen by assembling a trusted advisory team, amid King Charles' ongoing cancer treatment. During a heartfelt visit to Colchester Hospital on Wednesday, Kate opened up about the emotional aftermath of her cancer treatment. She described this chapter of her life as "really, really difficult," sharing how challenging it was to transition back to everyday life. "You put on a sort of brave face, stoicism through treatment," she explained, per Page Six. "Treatment's done, then it's like, 'I can crack on, get back to normal,' but actually [that's not the case]." Although no longer under active medical supervision, the 43-year-old royal admitted that she can not "function normally at home as [she] perhaps once used to." She emphasized the importance of having support during this phase of recovery: "[Having] someone to help talk you through that, show you and guide you through that sort of phase that comes after treatment … is really valuable." Kate acknowledged that healing doesn't happen overnight, noting that finding a "new normal … takes time." "It's a roller coaster, it's not smooth, like you expect it to be. But the reality is, you go through hard times," the princess added. Kate first revealed her cancer diagnosis in March 2024, following a private two-month recovery period after undergoing abdominal surgery. At the time, she shared, "[Prince] William and I have been doing everything we can to process and manage this privately for the sake of our young family." By September 2024, Kate had completed her chemotherapy, and in a January update, she shared the uplifting news that she was cancer-free. Despite the good news, she acknowledged that the road to recovery wasn't immediate. "I remain focused on recovery," she wrote. "As anyone who has experienced a cancer diagnosis will know, it takes time to adjust." Over the past few months, the Princess of Wales has been gradually returning to public life. In June, she made a radiant appearance at Trooping the Colour with her children, sweetly coordinating in matching blue outfits with Princess Charlotte. However, Kate unexpectedly withdrew from the Royal Ascot last month, a decision that sparked renewed concern about her ongoing recovery. The Princess of Wales, who had been slated to attend the prestigious event alongside William, was listed in the official program as part of the royal carriage procession. Her sudden absence, confirmed by Kensington Palace, came as a surprise to many. A palace aide, speaking anonymously, shared that Kate was "disappointed" to miss the occasion. The official emphasized that she's still learning how to strike the "right balance" as she eases back into public life while prioritizing her health. Royal expert Ingrid Seward echoed this sentiment of the palace aide in an interview with HELLO! Magazine. "Kate might be back, but she's doing it sensibly and on her own terms," Seward explained. "Her priorities have changed and she's listening to her body, instead of being a people pleaser. She's absolutely got to be strict with herself and say: 'No, I can't do this.'" Seward added: "Maybe we've been lulled into a sense that we'll be seeing her all the time again, because she looks so amazing. But it must be an effort to look like that when you're not 100% full of energy." Meanwhile, Kate and William are said to be quietly laying the groundwork for their eventual roles as king and queen, taking careful steps to ensure a smooth transition when the time comes. According to People Magazine, the couple, along with their close advisors, are increasingly focused on "building a trusted team of advisors." Though King Charles continues to carry out his royal duties while undergoing cancer treatment, his health has added a new sense of urgency to the planning. Royal commentator Hilary Fordwich told Fox News Digital that the Prince and Princess of Wales are strategically building a strong, trusted team to support them. "They're being smart and deliberate about this next chapter," Fordwich said. "Given the king's condition, the need to be fully prepared has become more pressing than it was just a few years ago." "Prince William and Princess Catherine are indeed discreetly assembling a top-notch, extremely competent and reliable team to guide them through the coming transition," Fordwich continued. "There is now more urgency than anticipated just a few years ago due to King Charles' health concerns."

Associated Press
an hour ago
- Associated Press
Dianetics Running Teams Celebrate 75th Anniversary of Dianetics with Races Across the U.S. from Austin to Los Angeles
LOS ANGELES, Calif., July 2, 2025 (SEND2PRESS NEWSWIRE) — As the world marks the 75th anniversary of the groundbreaking book ' Dianetics: The Modern Science of Mental Health,' Dianetics Running Teams are hitting the pavement from Austin to Los Angeles, promoting mental clarity and physical fitness through participation in races nationwide, the Church of Scientology International announced today. This milestone year highlights the enduring impact of Dianetics, first published in 1950, and its ongoing mission to support well-being through community engagement and athletic endeavors. At the recent inaugural Old Zoo Half Marathon in Griffith Park, Los Angeles, the Dianetics Running Team made a strong showing, securing third place overall in the half marathon team competition. Individual achievements included John's second-place finish in the 60–64 age group for the half marathon and Neal's victory in the 70+ age group for the 12K distance. Team members Curt, Shawn, James, and John competed in the half marathon, while Matt and Neal represented the team in the 12K. The event, praised for its scenic, shaded course and smooth organization, underscored the team's commitment to blending athletic achievement with the message of mental health awareness that has defined Dianetics for over seven decades. The Dianetics Running Teams draw inspiration from a rich history of athletic excellence, dating back to their remarkable success in the 1990s United States Corporate Athletics Association (USCAA) Marathon Championships. In 1993, the Dianetics team clinched first place in the Los Angeles Marathon corporate competition with an impressive combined time of 11:38:37 across 42 finishers, outpacing major corporations like AT&T. This legacy of competitive spirit continues to fuel their participation in contemporary events, including the annual Holiday Classic in Clearwater, Florida—now in its 35th year—and the 'Say No To Drugs Holiday Classic' in Los Angeles, which has drawn thousands of athletes to support drug-free living. Beyond competition, the Dianetics Running Teams embody personal transformation. One team member shared a powerful story of overcoming a life-altering injury at age 12 that left him unable to use his arms properly. Through Dianetics auditing techniques, he regained his confidence and competitive edge, eventually qualifying for national canoeing championships despite medical prognoses. His journey reflects the profound impact of Dianetics, that motivates his involvement in the running team to spread awareness of its benefits. From Austin's vibrant running community to the iconic trails of Los Angeles, Dianetics Running Teams are marking this historic anniversary by fostering community spirit and promoting the dual importance of mental and physical health. Supported by the Church of Scientology these teams continue to inspire runners of all levels to pursue self-improvement and a balanced lifestyle. For more information about Dianetics Running Teams and their upcoming events, or to learn about the 75th anniversary celebrations of Dianetics: The Modern Science of Mental Health, please contact [email protected]. About Dianetics: First published in 1950, Dianetics: The Modern Science of Mental Health by L. Ron Hubbard introduced a revolutionary approach to mental well-being. Its principles continue to inspire millions worldwide, with initiatives like the Dianetics Running Teams, promoting health, clarity, and community engagement through athletic programs. MULTIMEDIA: Photo link for media: Photo caption: Members of the Dianetics Running Team in Austin proudly display their team spirit, celebrating the 75th anniversary of 'Dianetics: The Modern Science of Mental Health' with a commitment to mental clarity and physical fitness through running events across the city. NEWS SOURCE: Church of Scientology International Keywords: Religion and Churches, Dianetics Running Teams, 75th Anniversary of Dianetics, races, L Ron Hubbard, LOS ANGELES, Calif. This press release was issued on behalf of the news source (Church of Scientology International) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P127424 APNF0325A To view the original version, visit: © 2025 Send2Press® Newswire, a press release distribution service, Calif., USA. RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT. Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.
Yahoo
2 hours ago
- Yahoo
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease
Analysis of liver sinusoidal endothelial cells ('LSEC') from screening and end of treatment biopsies in the Phase 2b NATIVE study showed evidence of LSEC capillarization in patients without MASH, and a further increased capillarization in patients with MASH In addition, in the subgroup of patients without MASH, there was higher LSEC capillarization in patients with MASLD than those with normal histology LSEC capillarization observed in patients was strongly associated with liver fibrosis and to a lesser extent inflammation End of treatment biopsies from Phase 2b NATIVE showed improvement in LSEC capillarization in patients with MASH and treated with lanifibranor compared to placebo In addition, using two preclinical models, lanifibranor demonstrated effects extending beyond capillarization reversal, normalizing portal pressure and intrahepatic vascular resistance These effects in the preclinical models appear more pronounced than those observed with single PPAR agonists, suggesting that as a pan-PPAR agonist, lanifibranor could represent a comprehensive therapeutic approach for MASH, fibrosis regression, and the prevention of progression to cirrhosis Daix (France), New York City (New York, United States), July 2, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ('Inventiva' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ('MASH'), today announces the publication in Journal of Hepatology Reports, a peer-reviewed, scientific journal, of results from the Phase 2b NATIVE clinical trial and preclinical study evaluating the effects of lanifibranor on liver sinusoidal endothelial cells in Metabolic dysfunction-associated steatotic liver disease ('MASLD') and MASH. Kris V. Kowdley MD, Director of the Liver Institute Northwest, Washington said: 'The liver sinusoidal endothelial cells (LSECs) play a crucial role in the vascular changes seen in liver diseases, including MASH and cirrhosis. Capillarization of these cells appears early, even before the onset of MASH. The results from the Phase 2b NATIVE trial with lanifibranor show a correlation between LSEC capillarization and both the stage of fibrosis and inflammation, along with evidence suggesting that lanifibranor can reduce this capillarization. These findings strengthen our confidence in lanifibranor's potential to help prevent progression to cirrhosis and associated clinical events.' The LSEC alteration was evaluated using CD34 staining in the Phase 2b NATIVE biopsies, which showed a higher density of CD34 staining in patients with MASLD or MASH compared to patients without CD34 staining was shown to be associated with liver fibrosis and to a lesser extent with inflammation. CD34 staining on the NATIVE liver biopsies was reduced in a dose-dependent manner following the treatment with lanifibranor for 24 weeks. These data suggest that lanifibranor potentially reduces LSEC capillarization, a key driver in the progression of cirrhosis, in patients with MASH and fibrosis. Two preclinical models for MASLD and MASH showed that vascular modifications appear at early stages of disease development even before inflammation and fibrosis. Moreover, these models showed that the effects of lanifibranor potentially extend beyond capillarization reversal, normalizing intrahepatic vascular resistance (IHVR) demonstrated by normalization of portal vein pressure and the ex-vivo measured transhepatic pressure gradient. These effects were superior to those observed with single PPAR dysfunction is increasingly recognized as a key contributor to the progression of chronic liver diseases. LSEC dysfunction is characterized by loss of fenestrations (defenestration) and by capillarization, which disrupts hepatic microcirculation, leading to impaired substrate exchange, increased intrahepatic vascular resistance, and elevated portal pressure. This dysfunction also promotes a pro-inflammatory and pro-fibrotic environment, facilitating the progression from early-stage liver disease to more advanced conditions such as fibrosis and cirrhosis. The histological evaluation from the NATIVE Phase 2b trial demonstrated that LSEC capillarization occurs in the very early stage of the disease. We believe the robust dataset from the NATIVE Phase 2b trial combined with the additional data from preclinical models, points to potential benefits of lanifibranor as a pan-PPAR agonist targeting the multiple components of the disease. Publication details Publication title: 'Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment.' Authors: Pierre-Emmanuel Rautou, Shivani Chotkoe, Louise Biquard, Guillaume Wettstein, Denise Van der Graaff, Yao Liu, Joris De Man, Christophe Casteleyn, Sofie Thys, Winnok H. De Vos, Pierre Bedossa, Michael P. Cooreman, Martine Baudin, Jean-Louis Abitbol, Philippe Huot-Marchand, Lucile Dzen, Miguel Albuquerque, Pierre Broqua, Jean-Louis Junien, Luisa Vonghia, Manal F. Abdelmalek, Wilhelmus J. Kwanten, Valérie Paradis, Sven M. Francque Online version: About lanifibranorLanifibranor, Inventiva's lead product candidate, is an orally available small molecule that acts to induce anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor ('PPAR') isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan-PPAR agonist in clinical development for the treatment of MASH. Inventiva believes that lanifibranor's moderate and balanced pan-PPAR binding profile contributes to the favorable tolerability profile that has been observed in clinical trials and preclinical studies to date. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of MASH. About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). Contacts Inventiva Pascaline Clerc EVP, Strategy and Corporate Affairs media@ +1 202 499 8937 Brunswick Group Tristan Roquet Montegon / Aude Lepreux / Julia Cailleteau Media relations inventiva@ +33 1 53 96 83 83 ICR Healthcare Patricia L. Bank Investor relations +1 415 513 1284Important NoticeThis press release contains certain 'forward-looking statements' within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, Inventiva's expectations with respect to forecasts and estimates with respect to Inventiva's pre-clinical programs and clinical trials, including design, protocol, duration, timing and costs of Inventiva's pre-clinical studies, and the results and timing thereof and regulatory matters with respect thereto, preclinical study data releases and publications, the information, insights and impacts that may be gathered from preclinical studies, clinical trials, the potential therapeutic benefits of lanifibranor, potential regulatory submissions, approvals and commercialization, the clinical development of and regulatory plans and pathway for lanifibranor, the expected benefit of having received Breakthrough Therapy Designation and Fast Track Designation, including its impact on the development and review timeline of Inventiva's product candidates and approvals, and future activities, expectations, plans, growth and prospects of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, 'believes', 'anticipates', 'expects', 'intends', 'plans', 'seeks', 'estimates', 'may', 'will', 'would', 'could', 'might', 'should', 'designed', 'hopefully', 'target', 'potential', 'opportunity', 'possible', 'aim', and 'continue' and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates due to a number of factors, including that interim data or data from any interim analysis of ongoing clinical trials may not be predictive of future trial results, the recommendation of the DMC may not be indicative of a potential marketing approval, Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva's ability to obtain financing and to enter into potential transactions, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of its product candidate, lanifibranor, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners' clinical trials may not support Inventiva's and its partners' product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require additional holds and/or additional amendments to Inventiva's clinical trials, Inventiva's expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH may not be realized and may not support the approval of a New Drug Application, Inventiva's ability to identify additional products or product candidates with significant commercial potential, Inventiva's expectations with respect to its pipeline prioritization plan and related workforce reduction, including potential benefits, expenses and consequences relating thereto, Inventiva's ability to execute on its commercialization, marketing and manufacturing capabilities and strategy, Inventiva's ability to successfully cooperate with existing partners or enter into new partnerships, and to fulfill its obligations under any agreements entered into in connection with such partnerships, the benefits of its existing and future partnerships on the clinical development, regulatory approvals and, if approved, commercialization of its product candidates, and the achievement of milestones thereunder and the timing thereof, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners' control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's and its partners' business, and pre-clinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by changes in law and regulations, unfavorable conditions in its industry, geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, the conflict in the Middle East and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including developments in international trade policies, global inflation, financial and credit market fluctuations, tariffs and other trade barriers, political turmoil, and natural catastrophes, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Please refer to the Universal Registration Document for the year ended December 31, 2024 filed with the Autorité des Marchés Financiers on April 15, 2025 and the Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission (the 'SEC') on April 15, 2025 for other risks and uncertainties affecting Inventiva, including those described under the caption 'Risk Factors' and in future filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements Attachment Inventiva - PR - Journal of Hepatology Reports - EN - 07 02 2025Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data